Journal of Diabetes and Its Complications
Volume 19, Issue 3 , Pages 123-127 , May 2005

Retinopathy and hypertension affect serum high-sensitivity C-reactive protein levels in Type 2 diabetic patients

  • Keiko Tsunoda

      Affiliations

    • Department of Clinical Laboratory Medicine, Faculty of Medicine, Wakayama Medical University, 811-1 Kimi-idera, Wakayama 641-8509, Japan
    • ,
  • Mikio Arita

      Affiliations

    • Faculty of Nursing, Wakayama Medical University, 811-1 Kimi-idera, Wakayama 641-8509, Japan
    • ,
  • Mariko Yukawa

      Affiliations

    • Department of Central Laboratories, Wakayama Medical University Hospital, Japan
    • ,
  • Minoru Ueyama

      Affiliations

    • Department of Central Laboratories, Wakayama Medical University Hospital, Japan
    • ,
  • Machi Furuta

      Affiliations

    • Department of Clinical Laboratory Medicine, Faculty of Medicine, Wakayama Medical University, 811-1 Kimi-idera, Wakayama 641-8509, Japan
    • ,
  • Takayuki Nakagawa

      Affiliations

    • The First Department of Medicine, Faculty of Medicine, Wakayama Medical University, 811-1 Kimi-idera, Wakayama 641-8509, Japan
    • ,
  • Kishio Nanjo

      Affiliations

    • The First Department of Medicine, Faculty of Medicine, Wakayama Medical University, 811-1 Kimi-idera, Wakayama 641-8509, Japan
    • ,
  • Tokio Sanke

      Affiliations

    • Department of Clinical Laboratory Medicine, Faculty of Medicine, Wakayama Medical University, 811-1 Kimi-idera, Wakayama 641-8509, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 73 441 0656; fax: +81 73 445 9459

Received 22 September 2003 ,Revised 19 May 2004 ,Accepted 11 August 2004.

References 

  1. Albert MA, Daielson E, Rifai N, Ridker PM PRINCE Investigator. Effect of statin therapy on C-reactive protein levels. The Pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64–70
  2. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, et al. The relation of markers of inflammation to the development of glucose disorders in elderly. The cardiovascular heart study. Diabetes. 2001;50:2384–2389
  3. Bertin E, Nguyen P, Guenounou M, Durlach V, Potron G, Leutenegger I. Plasma level of tumor necrosis factor-alpha (TNF-α) are essentially dependent on visceral fat amount in type 2 diabetic patients. Diabetes & Metabolism. 2000;26:178–182
  4. Chul Sung K, Suh JY, Kim JH, Kang JH, Kim H, Lee MH, et al. High sensitivity c-reactive protein as an independent risk factor for essential hypertension. American Journal of Hypertension. 2003;16:429–433
  5. Doggen CJM, Berckmans RJ, Sturk A, Manger CV, Rosendaal FR. C-reactive protein. Cardiovascular risk factors and the association with myocardial infarction in men. Journal of Internal Medicine. 2000;248:406–414
  6. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the insulin resistance atherosclerosis study. Kidney International. 2000;58:1703–1710
  7. Ford ES. Body mass index, diabetes, and C-reactive protein among US adults. Diabetes Care. 1999;22:1971–1977
  8. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GDO, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51:1596–1600
  9. Frohlich M, Boeing H, Imhof A, Muche R, Berg G, Brenner H, et al. Association between C-reactive protein and features of the metabolic syndrome. Diabetes Care. 2000;23:1835–1839
  10. Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI, et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. Journal of the American College of Cardiology. 2000;36:1774–1780
  11. Kathryn CB, Edward DJ, Nelson MS, Lam TH, Sidney CF, Karen SL. C-reactive protein predicts the deterioration of glycemia in Chinese subjects with impaired glucose tolerance. Diabetes Care. 2003;26:2323–2328
  12. Kilpatrick ES, Keevil BG, Jagger C, Spooner RJ, Small M. Determinants of raised C-reactive protein concentration in type 1 diabetes. Quarterly Journal of Medicine. 2000;93:231–236
  13. Lee IT, Sheu WH, Lin SY, Lee WJ, Song YM, Liu HC. Simvastatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetes with hyperlipidemia. Journal of Diabetes and its Complications. 2002;16:382–385
  14. Navarro JF, Mora C, Maca M, Garca J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. American Journal of Kidney Diseases. 2003;42:53–61
  15. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511
  16. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007–2011
  17. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New England Journal of Medicine. 2000;342:836–843
  18. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hyperclolesterolemia. Circulation. 2001;103:1191–1193
  19. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clinical Chemistry. 2001;47:403–411
  20. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clinical Chemistry. 1999;45:2136–2141
  21. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–126
  22. Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilatation in type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism. 2002;87:563–568
  23. Tominaga M. Proposal from a study of diabetes mellitus prevalence survey in Funagato Town. Diabetic Complications. 2000;14:92–93
  24. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not inpaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920–924
  25. Tracy RP. Inflammation in cardiovascular disease. Circulation. 1998;97:2000–2002
  26. van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C. Strong decrease of high sensitive C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes. Atherosclerosis. 2003;166:129–135
  27. Visser M, Bouter LM, McQuillan G, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131–2135

PII: S1056-8727(04)00093-5

doi: 10.1016/j.jdiacomp.2004.08.001

Journal of Diabetes and Its Complications
Volume 19, Issue 3 , Pages 123-127 , May 2005

Article Tools